Indridi Benediktsson Dr. Indridi Benediktsson Health Research DG Research – European Commission March 2008 International cooperation in the EU Framework.

Indridi Benediktsson

Dr. Indridi BenediktssonHealth Research

DG Research – European Commission

March 2008

International cooperation in the EU Framework Programmes

Health research


Why research at European level?

Pooling and leveraging resources To achieve critical mass Complement private investments Interoperability and complementarity

Fostering capacity and excellence in S&T Stimulate training, mobility and career development of

researchers Improve S&T capabilities Stimulate competition in research

Better integration of European R&D Scientific base for pan-European policy Coordination of national policies Comparative research at EU-level Dissemination of research results


The role of the EC in research

Funding agency Supporting research done by multi-national,

multi-disciplinary teams in pre-defined areas through FPs

Objective: to strengthen the S+T basis to increase competitiveness of industry and raise international standing of Europe

Preparing + implementing policies European Research Area, 3% of GDP for R&D,

European Patent, EMEA, TPs etc.


Linking scientific and policy interests

The policy level needs to know what issues can and should be tackled by science

The scientists must formulate their future vision to fit the needs of society, if they want a greater share of the taxpayer’s money

EC acts as translator between the two “worlds”

Decision power lies with the EP and Council (MS)

Local policy makers need input from local scientific teams in order to support (or not) suggestions from the EC



EC programmes bring down barriers between countries:

multinational consortia researchers from any country in the world can participate coordination among national funding programmes

between different types of organizations: universities, research centres, SMEs, large companies, etc.

between disciplines: focus on interdisciplinary and translational research

and encourage mobility: Marie Curie fellowships for researchers and for host institutes, including ingoing & outgoing grants



FP7 Health

Main policy drivers: Improving health of European citizens

Increasing competitiveness of European health-related industries and businesses

Addressing global health issues, e.g. emerging epidemics

Budget: €6 billion over 7 years (2007-2013)


Health research in FP7

Pillar 1:Biotechnology,

generic tools and medical

technologies for human

health

Pillar 2:Translating research for

human health

Pillar 3:Optimising the delivery

of health care to European

citizens

Funding schemes targeted at International Cooperation: SICA

Health of the Ageing population

Child Health

Funding schemes targeted at Small and Medium-sized Enterprises


1: Biotechnology, generic tools and technologies

High-throughput research (enhancing data generation, standardisation, acquisition & analysis).

Detection, diagnosis and monitoring (with emphasis on non-invasive or minimally invasive approaches).

Innovative therapeutic approaches and interventions(with potential application in many diseases and disorders).

Predicting suitability, safety and efficacy of therapies

Collaborative researchin Health


2: Translating research for human health

Integrating biological data and processes: (large-scale data gathering, systems biology)

Research on the brain and related diseases, human development and ageing

Infectious diseases: (antimicrobial drug resistance, HIV/AIDS, malaria, TB, emerging epidemics)

Other major diseases: (cancer, cardiovascular disease, diabetes/obesity; rare diseases; and other chronic diseases)



3: Optimising the delivery of health care

Enhanced health promotion and disease prevention

Translating clinical research into clinical practice

Quality, solidarity and sustainability of health systems



International Collaboration

-issues at stake:A) Development assistance

policy objectives, e.g. Millennium Development Goalstargets: low income countries, e.g. ACP

B) Strengthening competitiveness collaboration for mutual gainscompetition between the industrialised countries (e.g. attracting excellence)targets: more developed countries (e.g. BRIC)

C) Science diplomacycollaborating w. industrialised countries“ice breaking” when collaborating w. new partner countriesputting “flesh on the bones” of S+T agreementstargets: OECD, all 3rd countries

-All in the context of Excellence


1. All activities open for International Cooperation1. All activities open for International Cooperation International Cooperation Partner Countries (ICPCs) can participate in projects and receive

EC funding as in FP6 Industrialised countries may be funded if their participation is seen as essential for the project Minimum number of participants: 3 from MS/AS

International Cooperation

in FP73 different avenues:

2. Specific International Cooperation Actions2. Specific International Cooperation Actions Address specific issues that partner countries face or have a global

character, on the basis of mutual interest and benefit Minimum number of participants: 2+2 (2 from MS/AS + 2 from ICPCs)

3. Bilateral agreements for targeted co-funding3. Bilateral agreements for targeted co-funding Individual agreements with specific countries (CN, RU…)


International Cooperation

in FP7 Health

Programme level cooperation

In large scale In large scale projectsprojects where tasks can be divided where tasks can be divided Funding agencies and scientists design the “Meta”-project – agreeing on broad common principles Each agency issues calls according to own rules Projects are funded and required to work together Otherwise no contractual link


Programme level cooperation with the USA - examples

• International Knock – out Mouse Consortium (IKMC) (2007) (EUCOMM – EU, KOMP – Canada, NORCOMM – USA)

• Human Metagenomics Consortium (in prep.) 2008 (EC, NIH, Japan? …)

• International Cancer Genomics Consortium (ICGC) (in prep.) (EC, Genome Canada, NIH...)

• “ Affinity Reagents for Human Proteome ” (in prep. – first meeting in Stockholm, March 2008)


3rd Country Participation

in FP6 Health

In total: 214 participants from 51 third countriescommitted budget: 30 million Euro

Number of participants (if 5 or more)

0

5

10

15

20

25

30

35

China

RussiaUSA

Australia

Canada

South A

frica

Argentin

a

Ukrain

eIn

dia

Brazil

Kenya

Serbia

Number of 3rd country participants in FP6 Health projects


3rd Country Participationin FP7 Health: 1st call 2007

Number of participants (if 5 or more)

Number of 3rd country participants in FP7 Health proposals

0

5

10

15

20

25

30

35

40

USA

Russia

China

South A

frica

India

Australia

Canada

Egypt

Argentin

a

Ukrain

e

Viet N

amJa

pan

Tanza

nia

In total: 263 participants from 54 third countries

0

5

10

15

20

25

30

35

40

USA

Russia

China

South A

frica

India

Australia

Canada

Egypt

Argentin

a

Ukrain

e

Viet N

amJa

pan

Tanza

nia


3rd Country Participationin FP7 Health: 1st call 2007

Number of successful participants (if more

than 1)

Number of 3rd country participants in successful FP7 Health proposals

0

1

2

3

4

5

6

7

US

Russia

ChinaIn

dia

South

Afri

ca

Argenti

na

Colombia

Austra

lia

Canada

Viet N

am

Tanza

nia

Thaila

nd


Indridi BenediktssonIn total: 800 participants from 91 third countries

Health theme Outcome of 2nd call

Number of 3rd country participants in proposals (if ≥20)

0

20

40

60

80

100

120

India

China

USA

Brazil

Russi

a

Argen

tina

Egypt

S-Afri

ca

Colom

bia

Tunisi

a


Number of participants in successful proposals (if ≥4)

Health theme Outcome of 2nd call


0

5

10

15

20

25

30

India

USA

China

Austra

lia

S-Afri

ca

Canad

a

Russi

a

Argen

tina

Brazil

Viet N

am


Africa; 2,7

E-Asia; 2,1

N-Am; 1,7S-Asia; 1,7

S-Am; 1,5

SE-Asia; 1,5

EECA; 1,4

Other; 0,7

Geographical distribution of committed funds for non associated 3rd countries (million €)

First call 2006; total: 13.3 million, or 2.1% of the call budget


Africa; 8,4

S-Asia; 6

N-Am; 4,1

S-Am; 4

SE-Asia; 3,9

EECA; 2,5

E-Asia; 1

Other; 0,8

Geographical distribution of committed funds for non associated 3rd countries (million €)

Second call 2007; total: 30.7 million, or 5.4% of the call budget


0

1

2

3

4

5

6

7

8

9

Argentin

a

Brazil

Colom

bia

Mex

ico

Uruguay

Chile

Ecuad

or

Bolivia

Peru

Guatem

ala

Venez

uela

CSA-SA

CP-SICA

CP-FP

Health theme Results of first two calls

Nu

mb

er o

f p

arti

cip

ants


Health theme Results of first two calls

Nu

mb

er o

f p

arti

cip

ants

0

10

20

30

40

50

60

70

80

90

100

Coll Res SICA CA+SA

other ICPC

Lat. Am.


International Collaboration

in FP7 - HealthThe contextHEALTH is a political priority for most

countries in the world; industrialised, emerging economies and low income countries

Infectious diseases do not respect borders and can spread worldwide

“Rich world” diseases (cancer, diabetes…) also affect the developing countries and vice versa (Aids, TB…)

Treatments and cures are universal


Timeframe for FP7 projects

20122006 2007 20142008 2009 2010 20152011 2013 2016

Official duration of FP7 2007-2013

Projects resulting from FP7 calls operating

Results from FP7 projects in use

Last projects startFirst projects startFirst calls Last projects end

2017 2018 2019 2020 2021


How can EULARINET help?

in priority setting

– Centralise WP input from the region– Take stock of existing strengths

– No need to focus only on SICAs– Timing is important– Close involvement of relevant RTD units– Extensive argumentation

– No guarantee


Contacts in the Health Directorate

Acting Director –Manuel [email protected]

Medical and Public Health Research – [email protected]

Public Health sector – [email protected]

Infectious Diseases – [email protected]

Genomics and Systems Biology – [email protected]

Health Biotechnology – [email protected]

Coordination – [email protected]


Contacts & Information

Innovative Medicines Initiative (IMI)[email protected]://ec.europa.eu/research/health/imi/index_en.html

SME participation: [email protected]

International Cooperation: [email protected]

Framework Programme 7: http://cordis.europa.eu/fp7

Experts: http://cordis.europa.eu/research_openings


Information

• EU research: http://ec.europa.eu/research

• Seventh Framework Programme: http://ec.europa.eu/research/fp7

• Information on research programmes and projects:

http://cordis.europa.eu/

•

http://ec.europa.eu/research/research-eu/

• Information requests: http://ec.europa.eu/research/enquiries/


EC money

≠

Easy money

Indridi Benediktsson Dr. Indridi Benediktsson Health Research DG Research – European Commission March 2008 International cooperation in the EU Framework.

Documents

health slide

clinical research

research centres

research european commission

health promotion

sica health

health of european citizens

systems biology research